Order Article Reprints

Piñana JL, Heras I, Aiello TF, García-Cadenas I, Vazquez L, Lopez-Jimenez J, Chorão P, Aroca C, García-Vidal C, Arroyo I, et al. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients. Viruses. 2023; 15(10):2066. https://doi.org/10.3390/v15102066

Piñana, José Luis, Inmaculada Heras, Tommaso Francesco Aiello, Irene García-Cadenas, Lourdes Vazquez, Javier Lopez-Jimenez, Pedro Chorão, Cristina Aroca, Carolina García-Vidal, Ignacio Arroyo, and et al. 2023. "Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients" Viruses 15, no. 10: 2066. https://doi.org/10.3390/v15102066

Piñana, J. L., Heras, I., Aiello, T. F., García-Cadenas, I., Vazquez, L., Lopez-Jimenez, J., Chorão, P., Aroca, C., García-Vidal, C., Arroyo, I., Soler-Espejo, E., López-Corral, L., Avendaño-Pita, A., Arrufat, A., Garcia-Gutierrez, V., Arellano, E., Hernández-Medina, L., González-Santillana, C., Morell, J., ... Solano, C., on behalf of the Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). (2023). Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients. Viruses, 15(10), 2066. https://doi.org/10.3390/v15102066